Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL

October 31, 2023

a231030_00.png

a231030_01.png

Previous: 150 Party Organization Secretaries Visit CSPC

Next: CSPC's GLP-1 Targeted Drug Project Approved as a Major Technology Innovation Project

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat